Virginia Litwin
Research Subjects
Research Interests
Virginia Litwin has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Kelly Lundsten
Luminous Bioanalytical Consulting Fort Collins Colorado USA
2 shared publicationsLili Wang
National Institute of Standards and Technology (NIST) Gaithersburg Maryland USA
2 shared publicationsSteven Eck
AstraZeneca Gaithersburg Maryland
2 shared publicationsAbhishek Koladiya
Division of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics Stanford University Stanford California USA
1 shared publicationAlessandra Vitaliti
Novartis Institute for BioMedical Research Novartis Pharma AG Basel Switzerland
1 shared publication- Alessandra Vitaliti
Department of Chemical Science and Technologies, University of Rome “Tor Vergata”, Via della Ricerca Scientifica 1, 00133 Rome, Italy
1 shared publication
Latest Publications
- 30 December 2025
- Published by Wiley in Cytometry Part A
- Vol. 109 (1) , 5-41
Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2025 Conference Workshops
- 30 December 2025
- Published by Wiley in Cytometry Part A
- Vol. 109 (1) , 5-41
Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2025 Conference Workshops
- Open Access
- 24 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10263
Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies
Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.
- 24 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10263
Open AccessUsing Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies
Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.
- 22 August 2023
- Published by Wiley in Current Protocols
- Vol. 3 (8) , e868
Flow Cytometry Method Validation Protocols
Analytical method validation provides a means to ensure that data are credible and reproducible. This article will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry, along with practical procedures for four different types of validation. The first, Basic Protocol 1 (the limited validation protocol), is recommended for research and non‐regulated laboratories. Next, Basic Protocol 2) presents a reasonable, fit‐for‐purpose validation approach appropriate for biopharma and research settings. Basic Protocol 3 addresses the type of validation performed in clinical laboratories for moderate‐risk tests developed in house. Finally, Basic Protocol 4 describes the process that should be applied whenever a method is being transferred from one facility to another. All four validation plans follow the fit‐for‐purpose validation approach, in which the validation parameters are selected based on the intended use of the assay. These validation protocols represent the minimal requirement and may not be applicable for every intended use such as high‐risk clinical assays or data to be used as a primary endpoint in a clinical trial. The recommendations presented here are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). © 2023 Wiley Periodicals LLC.Basic Protocol 1: Limited validationBasic Protocol 2: Fit‐for‐purpose validation for biopharma and research settingsBasic Protocol 3: Validation for moderate clinical risk laboratory developed testsBasic Protocol 4: Transfer validationThis article was corrected on 25 January 2024. See the end of the full text for details.
- 22 August 2023
- Published by Wiley in Current Protocols
- Vol. 3 (8) , e868
Flow Cytometry Method Validation Protocols
Analytical method validation provides a means to ensure that data are credible and reproducible. This article will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry, along with practical procedures for four different types of validation. The first, Basic Protocol 1 (the limited validation protocol), is recommended for research and non‐regulated laboratories. Next, Basic Protocol 2) presents a reasonable, fit‐for‐purpose validation approach appropriate for biopharma and research settings. Basic Protocol 3 addresses the type of validation performed in clinical laboratories for moderate‐risk tests developed in house. Finally, Basic Protocol 4 describes the process that should be applied whenever a method is being transferred from one facility to another. All four validation plans follow the fit‐for‐purpose validation approach, in which the validation parameters are selected based on the intended use of the assay. These validation protocols represent the minimal requirement and may not be applicable for every intended use such as high‐risk clinical assays or data to be used as a primary endpoint in a clinical trial. The recommendations presented here are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). © 2023 Wiley Periodicals LLC.Basic Protocol 1: Limited validationBasic Protocol 2: Fit‐for‐purpose validation for biopharma and research settingsBasic Protocol 3: Validation for moderate clinical risk laboratory developed testsBasic Protocol 4: Transfer validationThis article was corrected on 25 January 2024. See the end of the full text for details.
- Open Access
- 1 February 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-7
Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report
This conference report summarized a full-day workshop, “best practices for the development and fit-for-purpose validation of biomarker methods,” which was held prior to the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Congress, San Antonio, TX, November 2019. The purpose of the workshop was to bring together thought leaders in biomarker assay development in order to identify which assay parameters and key statistical measures need to be considered when developing a biomarker assay. A diverse group of more than 40 scientists participated in the workshop. The workshop and subsequent working dinner stimulated robust discussion. While a consensus on best practices was not achieved, some common themes and major points to consider for biomarker assay development have been identified and agreed on. The focus of this conference report is to summarize the presentations and discussions which occurred at the workshop. Biomarker assay validation is a complex and an evolving area with discussions ongoing.
- 1 February 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-7
Open AccessBest practices for the development and fit-for-purpose validation of biomarker methods: a conference report
This conference report summarized a full-day workshop, “best practices for the development and fit-for-purpose validation of biomarker methods,” which was held prior to the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Congress, San Antonio, TX, November 2019. The purpose of the workshop was to bring together thought leaders in biomarker assay development in order to identify which assay parameters and key statistical measures need to be considered when developing a biomarker assay. A diverse group of more than 40 scientists participated in the workshop. The workshop and subsequent working dinner stimulated robust discussion. While a consensus on best practices was not achieved, some common themes and major points to consider for biomarker assay development have been identified and agreed on. The focus of this conference report is to summarize the presentations and discussions which occurred at the workshop. Biomarker assay validation is a complex and an evolving area with discussions ongoing.
- Open Access
- 17 November 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 100 (6) , 619-621
Issue Highlights—November 2021
- 17 November 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 100 (6) , 619-621
Open AccessIssue Highlights—November 2021
- 16 September 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (21) , 1591-1595
Progress Towards Global Standardization for Quantitative Flow Cytometry
- 16 September 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (21) , 1591-1595
Progress Towards Global Standardization for Quantitative Flow Cytometry
- 19 April 2017
- Published by Springer Nature
- p. 133-152
Validation—The Key to Translatable Cytometry in the 21st Century
- 19 April 2017
- Published by Springer Nature
- p. 133-152
Validation—The Key to Translatable Cytometry in the 21st Century
- 23 August 2016
- Published by Springer Nature
- p. 127-140
New Technologies for Cellular Analysis